News >

Trastuzumab Biosimilar May Alleviate Financial Toxicity in HER2+ Breast Cancer

Kristi Rosa
Published: Wednesday, Oct 02, 2019

Chen Fu, MD, an assistant professor of medicine at NYU School of Medicine

Chen Fu, MD

Preclinical and clinical data have demonstrated the equivalence of CT-P6 (Herzuma; trastuzumab-pkrb) to reference trastuzumab (Herceptin), said Chen Fu, MD, and the integration of the product into clinical practice could increase patient access by alleviating some of the financial toxicity associated with treatment.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x